You just read:

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

News provided by

Astellas Pharma Inc.

Jul 13, 2018, 14:30 ET